MiMedx Group Lowered to Market Perform at Northland Securities (MDXG)
MiMedx Group (NASDAQ:MDXG) was downgraded by investment analysts at Northland Securities from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The analysts noted that the move was a valuation call.
MDXG has been the subject of a number of other recent research reports. Analysts at Canaccord Genuity raised their price target on shares of MiMedx Group to $12.00 in a research note to investors on Friday, December 20th. Separately, analysts at Northland Capital Partners raised their price target on shares of MiMedx Group from $5.00 to $6.00 in a research note to investors on Friday, November 1st. They now have an “outperform” rating on the stock.
Shares of MiMedx Group (NASDAQ:MDXG) traded down 7.71% during mid-day trading on Monday, hitting $7.78. The stock had a trading volume of 1,292,169 shares. MiMedx Group has a 52 week low of $1.81 and a 52 week high of $8.80. The stock’s 50-day moving average is $7.16 and its 200-day moving average is $5.94. The company’s market cap is $761.3 million.
MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.00 EPS for the quarter. The company had revenue of $16.10 million for the quarter, compared to the consensus estimate of $15.23 million. The company’s quarterly revenue was up 102.5% on a year-over-year basis. Analysts expect that MiMedx Group will post $-0.04 EPS for the current fiscal year.
MiMedx Group, Inc is a development-stage company. The Company is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.